Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Indices fluctuate due to price swings in components and shifting sentiment. This short intro outlines the main causes of index volatility.
22,408 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
A major strategic move lands in Voyager Technologies’ lap as it closes the Astrobotic acquisition while securing a he...
A legendary investor makes a bold AI move. He recently closed a position in a company famous for aggressive AI spend ...
When headlines shout that berkshire hathaway sold mastercard, investors feel the pull to imitate. This guide explains...
The Trade Desk slid again amid reports of agency cautions and analyst downgrades. This piece explains the drivers, wh...
After Microsoft's pullback, savvy investors look for durable megacap ideas. This guide highlights three top megacap s...
Spotlighting two strong growth names that could exceed Summit Therapeutics in a year. Learn the catalysts, risks, and...
AMD delivered a blockbuster quarter, topping expectations on both earnings and revenue. The market response was elect...
The market is hovering around record levels, but does that mean you should sit on the sidelines? Not necessarily. Thi...
May could mark a turning point for investors eyeing the clean energy revival. This article breaks down two nuclear en...
The AI boom isn’t over. If you felt you missed the first wave, these three resilient stocks deliver real AI leverage,...
Datadog’s stock rally reflects a larger trend: enterprises want visibility into cloud and AI spend. This article brea...